目錄:MedChemExpress LLC>>信號(hào)通路>> BAY1217389 | MCE
參考價(jià) | ¥ 650 |
參考價(jià) | ¥ 650 |
更新時(shí)間:2023-07-24 10:24:22瀏覽次數(shù):182評(píng)價(jià)
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,謝謝!
CAS | 1554458-53-5 | 純度 | 99.94% |
---|---|---|---|
分子量 | 561.5 | 分子式 | C??H??F?N?O? |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 2 mg |
貨號(hào) | HY-12859 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
產(chǎn)品活性:BAY 1217389是具有高效性和選擇性的(MPS1)激酶抑制劑,IC50值小于10 nM。
研究領(lǐng)域:Cell Cycle/DNA Damage | Cytoskeleton
作用靶點(diǎn):Mps1
In Vitro: BAY 1217389 inhibits Mps1 kinase activity with IC50 value below 10 nM while showing an excellent selectivity profile. In cellular mechanistic assays BAY 1217389 abrogates nocodazole-induced SAC activity and induces premature exit from mitosis resulting in multinuclearity and tumor cell death. BAY 1217389 efficiently inhibits tumor cell proliferation in vitro.
In Vivo: BAY 1217389 achieves moderate efficacy in monotherapy in tumor xenograft studies. However, in line with its unique mode of action, when combines with paclitaxel, low doses of Mps1 inhibitor reduces paclitaxel-induced mitotic arrest in line with weakening of SAC activity. As a result, combination therapy strongly improves efficacy over paclitaxel or Mps1 inhibitor monotreatment at the respective MTDs in a broad range of xenograft models including those showing acquired or intrinsic paclitaxel-resistance. BAY 1217389 shows good tolerability without adding toxicity to paclitaxel monotherapy.
相關(guān)產(chǎn)品:TC-Mps1-12 | Mps1-IN-1 dihydrochloride | AZ3146 | Mps1-IN-1 | Mps1-IN-3 hydrochloride | NMS-P715 | Mps1-IN-4 | BOS-172722 | RMS-07 | Mps-BAY2a | MPI-0479605 | Empesertib | CCT251455 | Mps1-IN-5 | Mps1-IN-2
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫(kù),我們致力于為全球科研客戶(hù)提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門(mén)信號(hào)通路及疾病領(lǐng);
• 產(chǎn)品種類(lèi)涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測(cè)分析,藥物篩選等專(zhuān)業(yè)技術(shù)服務(wù);
• 設(shè)有專(zhuān)業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國(guó)客戶(hù)實(shí)驗(yàn)驗(yàn)證;
• Nature, Cell, Science 等多種頂級(jí)期刊及制藥 Patent 收錄了MCE客戶(hù)的科研成果;
• 專(zhuān)業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機(jī)構(gòu)建立了長(zhǎng)期的合作。
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)